Thursday, January 26, 2017

CCM Duopharma: To supply MYR300m human insulin. The group will deliver MYR300m of human insulin to the government over a three-year period under the Health Ministry's off-take agreement programme. The letter of award will allow CCM Pharmaceuticals to provide the front-end sales, marketing, distribution and support services for the supply of Biocon’s human insulin formulation to all the government's hospitals and Klinik Kesihatan. (Source: The Star)






Lafarge Malaysia | A long road to recovery
Yen Ling Lee







IGB REIT | 4Q16 earnings in line
Kevin Wong







MRCB-Quill REIT | 4Q16 in line
Kevin Wong








alt=break v:shapes="_x0000_i1025">


COMPANY RESEARCH





TP Revision





Lafarge Malaysia (LMC MK)
by Yen Ling Lee





Share Price:
MYR6.97
Target Price:
MYR4.55
Recommendation:
Sell




A long road to recovery

4Q16 earnings could be dismal amid the insurmountable stiff competition. While we think cement ASPs may improve on a mild cement demand recovery in 2017, the steep jump in coal cost could limit LMC’s earnings recovery. We cut our: (i) FY16-18 EPS by 62%/35%/16% and; (ii) TP to MYR4.55 (-26%; based on the updated mean PER of 26x on 2017 EPS [from 24x]). Valuation is demanding with the stock trading at 1-year forward PER of 39x and DY of 2.4% is also unattractive.



FYE Dec (MYR m)
FY14A
FY15A
FY16E
FY17E
Revenue
2,743.1
2,750.8
2,275.0
2,476.3
EBITDA
493.5
509.4
281.2
427.1
Core net profit
256.0
251.0
53.5
148.1
Core EPS (sen)
30.1
29.5
6.3
17.4
Core EPS growth (%)
(30.2)
(1.9)
(78.7)
176.9
Net DPS (sen)
34.0
31.0
6.0
16.6
Core P/E (x)
23.1
23.6
110.7
40.0
P/BV (x)
1.9
1.9
1.9
1.9
Net dividend yield (%)
4.9
4.4
0.9
2.4
ROAE (%)
8.1
8.1
1.7
4.8
ROAA (%)
6.4
6.0
1.2
3.5
EV/EBITDA (x)
15.9
14.9
21.5
13.8
Net debt/equity (%)
net cash
1.0
4.1
net cash










TP Revision





IGB REIT (IGBREIT MK)
by Kevin Wong





Share Price:
MYR1.75
Target Price:
MYR1.85
Recommendation:
Buy




4Q16 earnings in line

4Q16 results and second interim gross DPU of 4.3sen (FY16: 8.7sen) were within expectations. 4Q16’s strong YoY earnings growth was driven by sustained occupancy rates, positive rental reversions, better opex management and lower finance costs. We raise FY17-18 earnings forecasts by ~3% p.a. and nudge up our DDM-TP by 5sen to MYR1.85 (cost of equity unchanged at 7.5%). Still our top BUY pick for retail M-REIT.



FYE Dec (MYR m)
FY15A
FY16A
FY17E
FY18E
Revenue
489.2
507.3
524.9
544.1
Net property income
342.8
361.1
373.6
387.7
Distributable income
291.0
317.3
328.0
342.8
DPU (sen)
7.4
7.8
8.4
8.7
DPU growth (%)
5.1
6.3
7.4
3.8
Price/DPU(x)
23.7
22.3
20.8
20.0
P/BV (x)
1.7
1.7
1.6
1.6
DPU yield (%)
4.2
4.5
4.8
5.0
ROAA (%)
4.9
5.4
5.6
5.8
Debt/Assets (x)
0.2
0.2
0.2
0.2










Results Review





MRCB-Quill REIT (MQREIT MK)
by Kevin Wong





Share Price:
MYR1.31
Target Price:
MYR1.35
Recommendation:
Buy




4Q16 in line

4Q16 results were within expectations. The lower 4Q16 core earnings were due to higher repair and maintenance costs, one-off non-property opex and steeper finance costs. Our earnings forecasts and DDM-TP of MYR1.35 (cost of equity: 7.5%) are intact. Maintain BUY on MQREIT as we remain positive on its office assets with long-term tenants while Menara Shell could provide stronger earnings growth upside.



FYE Dec (MYR m)
FY15A
FY16A
FY17E
FY18E
Revenue
115.2
131.8
185.1
187.5
Net property income
90.3
102.3
139.5
141.3
Distributable income
54.0
59.2
92.6
94.4
DPU (sen)
6.9
7.5
7.6
7.6
DPU growth (%)
(8.1)
8.8
0.4
0.9
Price/DPU(x)
18.9
17.4
17.3
17.1
P/BV (x)
1.0
0.6
1.0
1.0
DPU yield (%)
5.3
5.8
5.8
5.8
ROAE (%)
8.4
5.6
6.8
6.9
ROAA (%)
4.3
3.0
4.0
4.1
Debt/Assets (x)
0.4
0.4
0.4
0.4








NEWS


Outside Malaysia:

U.S: Sales of previously owned homes declined more than forecast in December, data from the National Association of Realtors data showed. Still, sales for the full year were the strongest since 2006. Contract closings fell 2.8% to a 5.49 million annual rate last month (forecast was 5.52 million) after a revised 5.65 million in November. Median sales price rose 4% from year earlier to USD 232,200. Inventory of available properties fell to 1.65 million, the lowest in records dating back to 1999. For all of 2016, existing home sales increased to 5.45 million, the highest since 2006, from 5.25 million a year earlier. (Source: Bloomberg)

Germany: Business sentiment unexpectedly slipped in January from its highest level in almost three years in a sign that momentum in Europe’s largest economy may have weakened at the start of the year. The Munich-based Ifo institute’s business climate index dropped to 109.8 from 111 in December. The report could raise concern that heightened political uncertainty will damp Germany’s economic prospects after growth in 2016 accelerated to the fastest pace in five years on the back of domestic spending. (Source: Bloomberg)

China: Central bank refrained from raising interest rates in its open-market operations, easing concern that it would tighten further after increasing the cost of medium-term loans. The People’s Bank of China offered CNY 15b (USD 2.2b) of 14-day reverse-repurchase agreements at 2.4%, and the same amount in 28-day contracts at 2.55%, according to a statement posted on its website. With CNY 200b of repos maturing, the operations resulted in a net withdrawal of CNY 170b, the most since October. (Source: Bloomberg)





Other News:

CCM Duopharma: To supply MYR300m human insulin. The group will deliver MYR300m of human insulin to the government over a three-year period under the Health Ministry's off-take agreement programme. The letter of award will allow CCM Pharmaceuticals to provide the front-end sales, marketing, distribution and support services for the supply of Biocon’s human insulin formulation to all the government's hospitals and Klinik Kesihatan. (Source: The Star)

Hua Yang: Acquires 10.86% of Magna Prima for MYR66.6m. The group has acquired 36 million shares in Magna Prima, equivalent to a 10.84% stake, for a purchase consideration of MYR66.6m, via an off-market direct business transaction. The acquisition is part of its objective to invest in strategic landbank, noting Magna Prima’s landbanks in Klang Valley which presents an opportunity for further collaboration between the two developers. (Source: The Edge Financial Daily)

Asia Poly: To diversify into property development. The cast acrylic products manufacturer plans to acquire the entire stake in High Reserve Land S/B (HRLSB) and diversify its business to include property development for a purchase consideration of MYR16m. HRLSB is involved in property development and is the registered owner of a parcel of commercial land measuring 1.9 acres with approved development order in Semenyih, Selangor. The proposed development for the land has a gross development value of RM39.9 million with a gross development profit of RM8.7 million. Asia Poly expects to undertake the proposed development in the fourth quarter this year. (Source: The Sun Daily)

Gadang: Improved margin boost Gadang’s quarterly earnings. Gadang net profit rose 57.5% to MYR23m or 10.62 sen per share for 2QFY17, from MYR18m or 7.4 sen per share a year ago. The company said this was mainly due to improved profit margins from construction activities and higher contributions from the property division. Revenue climbed 45% to MYR147.9m from MYR102m in 2QFY16, it said in a filing with Bursa Malaysia today. For the 6MFY17, Gadang’s net profit rose 15.6% to MYR44.6m or 16.97 sen per share, from MYR38.6m or 16.12 sen per share for 6MFY16. Revenue went up 0.44% to MYR252.5m from MYR251.4m in 6MFY16. (Source: The Edge Financial Daily)


No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Related Posts with Thumbnails